Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals
WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
98,50 €
12,57 %
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $63.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $80.00 to $91.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock, up previously from $70.00.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $66.00 to $72.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Stifel Nicolaus from $78.00 to $94.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $88.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Needham & Company LLC from $72.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $97.00 price target on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Wells Fargo & Company from $91.00 to $129.00. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Bank of America Corporation from $73.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $76.00 to $110.00. They now have an "outperform" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was given a new $95.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at Guggenheim from $119.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target raised by analysts at HC Wainwright from $80.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $138.00. They now have a "buy" rating on the stock.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Ratings data for RYTM provided by MarketBeat
Neueste Beiträge
StockNews_com in Axcelis Technologies diskutieren